PD-1 blockade in mediastinal gray-zone lymphoma
New England Journal of Medicine, 2017•Mass Medical Soc
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career
with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career
with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Mediastinal gray-zone lymphoma is intermediate between classic Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma. Three patients whose disease had become refractory to chemotherapy had impressive responses to PD-1 blockade.
The New England Journal Of Medicine